Managing Director, Alta Partners
Bob brings over 20 years of life sciences investing experience to his work at San Francisco-based Alta Partners. Most recently, Bob was a Senior Advisor to the Bill and Melinda Gates Foundation leading the organization’s Global Health Venture Initiative. Earlier, he was a General Partner at Frazier Healthcare Ventures and a member of the firm’s biopharma investment team. Prior to Frazier, Bob was with Domain Associates, where he started as a Kauffman Fellow in 1996 and became a Partner in 2000.
During his venture career, Bob has managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs), Proxima Therapeutics (acquired by Cytyc), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics, (NASDAQ: NEOT) and Glaukos Corporation (NYSE: GLKS). Bob was also an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs.
Before his venture career, Bob was with Pharmacia Biotech in sales, and also held a research position at Somatogen, a company developing a recombinant blood substitute.
Bob earned his MBA at the University of Virginia’s Darden School and his Bachelor’s degree from Middlebury College. He serves on the boards of the nonprofits One Revolution and the Foundation for Innovative New Diagnostics (FIND). He is a Kauffman Fellow (Class 2) and served as a mentor to Don O’Neil (Class 7). He was a founding Kauffman Fellows board member.